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In colorectal cancer (CRC) cells, mutant Kirsten rat sarcoma (KRAS) cell-autonomously imparts Warburg-like[@bib1] metabolic changes through induction of Glucose transporter 1 (GLUT-1) (SLC2A1).[@bib2], [@bib3] We previously reported that mutant KRAS has marked effects on the constituents of CRC exosomes, including proteins and enzymes involved in metabolism and glycolysis.[@bib4], [@bib5] The present studies were designed to test whether mutant KRAS exosomes can alter the metabolic state cell-nonautonomously in recipient colonic epithelial cells.

We isolated exosomes purified from Daniel L. Dexter derived 1 (DLD-1) cells, which contain 1 wild-type (WT) and 1 mutant *KRAS* allele, and those from DLD-1 isogenic cell variants genetically engineered to express only the WT *KRAS* allele (DKs-8) or only the mutant *KRAS* allele (DKO-1).[@bib6] Adding DKO-1 exosomes to DKs-8 cells significantly reduced glucose concentrations in the medium, suggesting increased cellular glucose uptake in these WT KRAS cells ([Figure 1](#fig1){ref-type="fig"}*A*). After 48-hour exposure to DKO-1 exosomes, a significantly higher percentage of recipient DKs-8 cells were in S and G2/M phases of the cell cycle ([Supplementary Figure 1](#figS1){ref-type="fig"}*A* and *B*), and cell number was increased at 120 hours ([Supplementary Figure 1](#figS1){ref-type="fig"}*C*). We next used the endogenous fluorescent characteristics of Nicotinamide adenine dinucleotide reduced (NADH) and Flavin adenine dinucleotide (FAD) to determine the relative balance between glycolysis and oxidative phosphorylation, as previously reported.[@bib7], [@bib8], [@bib9] Addition of mutant KRAS exosomes selectively and significantly increased the redox ratio in recipient normal mouse colonic cells cultured in Matrigel or on plastic ([Supplementary Figure 2](#figS2){ref-type="fig"}*A--D*) and WT KRAS DKs-8 cells ([Supplementary Figure 2](#figS2){ref-type="fig"}*E*).Figure 1**Mutant KRAS exosomes alter metabolism in vitro and in vivo.** (*A*) Glucose consumption of exosome-treated DKs-8 cells (N = 3 in triplicate). Data are plotted as means ± SD. (*B*) Normalized redox ratio of exosome-treated *Apc*^*Min/*+^ colonic tumors. (*C*) ^18^FSPG tumor-to-muscle uptake ratio in WT or *Apc*^*Min/*+^ mice injected with exosomes analyzed by 1-way analysis of variance followed by a post hoc Tukey test. \**P* \< .05.

To test whether mutant KRAS CRC exosomes function in vivo, we used the [A]{.ul}denomatous [p]{.ul}olyposis [c]{.ul}oli [m]{.ul}ultiple [i]{.ul}ntestinal [n]{.ul}eoplasia (*Apc*^*Min**/+*^) mouse model in which adenomas develop throughout the gastrointestinal tract. *Apc*^*Min/+*^ mice received intraperitoneal injections of DKs-8 or DKO-1 exosomes over 4 successive days. The redox ratio of tumors treated with DKO-1 exosomes was increased significantly ([Figure 1](#fig1){ref-type="fig"}*B* and [Supplementary Figure 3](#figS3){ref-type="fig"}*A*), suggesting that treatment with these mutant KRAS exosomes increases aerobic glycolysis in recipient tumor cells. We also performed (*S*)-4-(3-\[^18^F\]-fluoropropyl)-*L*-glutamic acid (^18^F-FSPG) positron emission tomography imaging 2 hours after the last injection of exosomes. ^18^F-FSPG is a novel positron emission tomography tracer that follows the import of cystine by the glutamate/cysteine antiporter *SLC7A11*, which is overexpressed in CRC.[@bib10] We found that *Apc*^*Min/+*^ mice injected with DKO-1 exosomes had a significant increase in ^18^F-FSPG uptake in the tumor region ([Figure 1](#fig1){ref-type="fig"}*C* and [Supplementary Figure 3](#figS3){ref-type="fig"}*B* and *C*), suggesting that mutant KRAS CRC exosomes can alter tumor cell metabolism in vivo.

Levels of GLUT-1 were increased in DKO-1 exosomes, as well as in cell lysates ([Figure 2](#fig2){ref-type="fig"}*A*). To test whether these mutant KRAS exosomes contained functional GLUT-1, we measured ^18^F-fluorodeoxyglucose incorporation. After 1 hour, ^18^F-fluorodeoxyglucose uptake was significantly higher in DKO-1 exosomes ([Figure 2](#fig2){ref-type="fig"}*B*). The purified exosomes showed the characteristic cup-shaped morphology and size reported for exosomes (40--100 nm) ([Supplementary Figure 4](#figS4){ref-type="fig"}*A* and *B*). Further purification of exosomes on an iodixanol density gradient showed that GLUT-1 was present in the fractions that contain established exosomal markers ([Supplementary Figure 4](#figS4){ref-type="fig"}*C*). Thus, mutant KRAS exosomes contain increased levels of functional GLUT-1.Figure 2**Exosomal GLUT-1 partially drives metabolic changes in recipient cells.** (*A*) Immunoblot analysis of cells and exosomes. After normalization to syntenin-1, levels of GLUT-1 were increased 2.5- and 3.1-fold in cell lysates and 3.1- and 5.2-fold in exosomes of DLD-1 and DKO-1 cells, respectively. (*B*) Percent ^18^F-fluorodeoxyglucose (^18^FDG) uptake in exosomes isolated from DKs-8 and DKO-1 cells (N = 3 in triplicate). (*C*) Fold-change of ^18^FDG uptake in exosomes isolated from parental and GLUT-1 KO DLD-1 cells. (*D*) nuclear magnetic resonance (NMR) determination of glutamate and lactate secretion in recipient DLD-1 GLUT-1 KO cells 43 hours after treatment with exosomes from parental DLD-1 or GLUT-1 KO cells (N = 2 in triplicate). Data are plotted as the means ± SD. \**P* \< .05.

Targeted disruptions of both alleles of *GLUT1* in DLD-1 cells (GLUT-1 knockout \[KO\]) led to loss of detectable GLUT-1 protein ([Supplementary Figure 4](#figS4){ref-type="fig"}*D*) and significantly reduced uptake of radiolabeled glucose in these exosomes ([Figure 2](#fig2){ref-type="fig"}*C*). None of the other glucose transporters tested (GLUT-2, GLUT-3, and GLUT-4) were detected in these exosomes (data not shown). We treated recipient DLD-1 GLUT-1 KO cells with exosomes isolated from DLD-1 parental or GLUT-1 KO cells for 43 hours and measured metabolite uptake and secretion using ^1^H-MRS. Compared with GLUT-1 KO exosomes, parental DLD-1 exosomes significantly increased secretion of lactate and glutamate in recipient cells ([Figure 2](#fig2){ref-type="fig"}*D*), suggesting that exosomal GLUT-1 contributes to the altered metabolic state of recipient cells.

In summary, we show that mutant KRAS exosomes are able to confer a Warburg-like effect on recipient colonic epithelial cells in vitro and in vivo. Increased functional exosomal GLUT-1 contributes to metabolic changes in recipient cells**.** These preliminary observations should prompt further study of exosomes in tumor metabolism.

Supplementary Materials and Methods {#appsec1}
===================================

Cell Culture and Reagents {#appsec1.1}
-------------------------

DLD-1, DKs-8, DKO-1,[@bib18] and DLD-1 GLUT-1 knockout cells were cultured as described previously.[@bib19], [@bib20] Propidium iodide was purchased from Invitrogen/Molecular Probes (Carlsbad, CA) and Hoechst was purchased from Sigma (St. Louis, MO).

Exosome Isolation and Characterization {#appsec1.2}
--------------------------------------

Exosomes were isolated from conditioned medium of DKs-8, DKO-1, DLD-1, and DLD-1 GLUT-1 KO cells as previously described.[@bib19] The diameter of exosomes (mean diameter, 50 nm) was obtained by nanoparticle tracking analysis (NanoSight, Wiltshire, United Kingdom; N = 4) as previously described.[@bib21] Electron microscopic imaging of exosomes was performed as previously described.[@bib21] Exosome pellets from DKO-1 cells were applied to the bottom of a discontinuous 5%--45% iodixanol (OptiPrep, Sigma-Aldrich) gradient and subjected to ultracentrifugation at 120,000 × *g* for 16 hours at 4°C using a TH-641 swinging bucket rotor (*k* factor of 114; Thermo Scientific \[Waltham, MA\]). Fractions (1 mL) were collected from the top of the gradient. Each fraction was diluted in phosphate-buffered saline and subjected to ultracentrifugation at 120,000 × *g* for 4 hours at 4°C using a SureSpin 630 (*k* factor of 219; Thermo Scientific) swinging bucket rotor.

Positron Emission Tomography Agent Synthesis {#appsec1.3}
--------------------------------------------

^18^F-Fluorodeoxyglucose was obtained commercially from PETNET (Siemens Healthcare Diagnostics, Inc, Tarrytown, NY) with an average radiochemical purity of 98.5% and specific activity of greater than 1000 Ci/mmol. ^18^F-FSPG was prepared as previously described.[@bib22]

^18^F-Fluorodeoxyglucose Incorporation {#appsec1.4}
--------------------------------------

A total of 50 μCi of ^18^F-fluorodeoxyglucose was added to 50 μL of DKs-8, DKO-1 DLD-1, or DLD-1 GLUT-1 KO cell-derived exosomes (1 mg/mL) in phosphate-buffered saline--HEPES, pH 7.2, and these samples were incubated at 37ºC for 1 hour. Ethylenimine (0.05%; Sigma) then was added and the solution was placed on an Isolute Phase Separator (Biotage, Charlotte, NC) fitted with a GF/B filter (Brandel, Inc, Gaithersburg, MD). Filters were washed, removed, and radioactivity was measured. Analysis was performed on at least 3 independent preparations of exosomes.

Immunoblot Analysis {#appsec1.5}
-------------------

Immunoblotting of cell lysates and exosomes was performed as previously described.[@bib20], [@bib21] Primary antibodies were epidermal growth factor receptor (1:1000; Millipore, Burlington, MA), syntenin-1 (1:5000; Abcam, Cambridge, MA), CD81 (1:1000; R&D Systems, Minneapolis, MN), GLUT-1 (1:1000, mouse; Abcam), GLUT-3 (1:1000; Abcam), and Alix (1:10,000; Cell Signaling, Danvers, MA). Secondary antibodies were rabbit IgG, horseradish peroxidase--linked antibody (1:1000; Sigma); mouse IgG, horseradish peroxidase--linked (1:5000; Jackson Immunoresearch, West Grove, PA); and IR-800 antibody (1:15,000; LI-COR, Lincoln, NE). Immunoblots were imaged by fluorescence detection using an Odyssey Fc Imaging System (LI-COR).

Measurement of Cellular Glucose Consumption {#appsec1.6}
-------------------------------------------

Before plating, 5 × 10^5^ DKs-8 cells were incubated with 50 μg exosomes or mock treated for 1 hour at 37°C. Cells were plated in 48-well dishes at 24,000 cells per well (in triplicate). Dulbecco\'s modified Eagle medium containing 5 mmol/L glucose (Sigma) and 3% fetal calf serum was added to each well. At the indicated times, medium was removed and stored at -80°C, and cell number was counted by measuring the fluorescent intensity of SYBR green (Invitrogen) staining. Glucose concentration in the medium was measured (normalized to cells per well, N = 3 in triplicate) using the Glucose Colorimetric Assay Kit (Cayman Chemical, Ann Arbor, MI), according to the manufacturer's directions.

Analysis of Cell-Cycle Progression {#appsec1.7}
----------------------------------

Before plating, 1.0 × 10^6^ DKs-8 cells were incubated with 100 μg exosomes or mock treated for 1 hour at 37°C, plated in 10-cm tissue culture dishes and Dulbecco\'s modified Eagle medium containing 5 mmol/L glucose, and 3% fetal calf serum was added and incubated for the indicated times. A total of 2 μg/mL of Hoechst 33342 (Sigma) was added to each plate 1 hour before harvest. Fifty thousand cells were washed and resuspended in 500 μL of phosphate-buffered saline supplemented with 3% fetal calf serum and the cell cycle was analyzed by flow cytometry. Samples were analyzed on a BD LSR II (Franklin Lakes, NJ) equipped with a solid-state UV laser. Doublet discrimination was used with appropriate pulse geometries[@bib23] (n = 3 in triplicate).

Isolation and Culturing of Mouse Colonic Cells {#appsec1.8}
----------------------------------------------

This procedure was performed as previously described.[@bib24], [@bib25]

Optical Metabolic Imaging {#appsec1.9}
-------------------------

After trypsinization and washing, DKs-8 or mouse colonic epithelial cells were centrifuged and resuspended at 1 × 10^6^ cells/mL in high-glucose Dulbecco\'s modified Eagle medium containing 3% fetal calf serum. Medium was supplemented with 100 μg/mL DKs-8 or DKO-1 cell--derived exosomes or 100 μL phosphate-buffered saline. Cells were incubated at 37°C for 60 minutes. Twenty thousand cells per well were plated in 24-well dishes and incubated for 48 hours at 37°C, and then optical metabolic imaging was performed. For colonoid experiments, cells were cultured in Matrigel (Corning, Tewksbury, MA) using minigut medium and then placed in 24-well agar-coated dishes. A total of 100 μg of DKs-8 or DKO-1 exosomes or 100-μL phosphate-buffered saline were added to the 400 μL of minigut medium in each well and orbitally rocked at 37°C for 1 hour followed by a 48- or 96-hour incubation at 37°C and then imaged.

Multiphoton optical metabolic imagining microscopy of NADH and FAD was performed on a custom-built, multiphoton fluorescence microscope (Bruker, Bremen, Germany), as previously described.[@bib26], [@bib27], [@bib28] Individual cells within the image were segmented using a customized routine in CellProfiler (Carpenter Lab at the Broad Institute of Harvard and MIT, Cambridge, MA)[@bib29] and the mean redox ratio for each cell was computed as the ratio of NADH fluorescence intensity divided by FAD fluorescence intensity.

In Vivo Imaging {#appsec1.10}
---------------

All procedures were approved by and performed in accordance with Vanderbilt University Animal Care and Use Committee guidelines. *Apc*^*Min/+*^ or WT (non--tumor-bearing) mice were screened for colonic tumors by colonoscopy. Before imaging, mice were injected for 4 consecutive days with 300 μg of DKs-8 or DKO-1 exosomes in 500 μL of phosphate-buffered saline. Mock-treated mice were injected with 500 μL of phosphate-buffered saline. For ^18^F-FSPG positron emission tomography imaging, mice were imaged with microPET Focus 220 (Siemens Preclinical Solutions, Knoxville, TN) and NanoSPECT/CT (Bioscan, Washington, DC) 2 hours after the final exosome or mock injection as previously described.[@bib30], [@bib31] Regions-of-interest determination was guided by anatomic magnetic resonance images (Varian, Inc, Palo Alto, CA). Similar-sized regions-of-interest were drawn around the tumors and hind limb muscles. The ^18^FSPG signal was expressed as the tumor-to-muscle uptake ratio. Comparisons between groups were performed using a 1-way analysis of variance followed by a Tukey test. For magnetic resonance images, multislice scout images were collected in all 3 imaging planes (axial, sagittal, and coronal) using a gradient echo sequence with a repetition time of 75 ms, echo time of 5 ms, slice thickness of 2 mm, flip angle of 35°, and an average of 4 acquisitions. Additional parameters included field of view of 50 mm × 50 mm and data matrix of 128 × 128 pixels.

Tissue Preparation {#appsec1.11}
------------------

Tissue were processed as previously described,[@bib32] except after positron emission tomography imaging when representative colonic tumors were dissected, they were then placed in Dulbecco\'s modified Eagle medium containing 10% fetal calf serum, and subjected to optical metabolic imaging.

Proton Magnetic Resonance (^1^H-MRS) of Cell Culture Media {#appsec1.12}
----------------------------------------------------------

Before plating, 5 million DLD-1 GLUT-1 KO cells were incubated with 500 μg exosomes isolated from parental DLD-1 cells or DLD-1 GLUT-1 KO cells, or mock treated for 1 hour with rotation at 37°C. Cells were plated in 10-cm dishes with 5 million cells per dish (in triplicate) with Dulbecco\'s modified Eagle medium containing 10% fetal calf serum depleted of bovine exosomes as previously described.[@bib33] After 43 hours, fresh cell culture medium and cell-conditioned medium were collected for metabolite measurements. A total of 50 μL D~2~O (Sigma-Aldrich) and 50 μL of 0.75% sodium 3-trimethylsilyl-2,2,3,3-tetradeuteropropionate in D~2~O (Sigma-Aldrich) were added to 500 μL media in 5-mm NMR tubes (Wilmad-LabGlass, Kingsport, TN) for chemical shift calibration and quantification. ^1^H-MRS spectra were acquired on an Avance III 600 MHz spectrometer equipped with a Triple Resonance CryoProbe (TCI) (Bruker) at 298 K with 7500-Hz spectral width, 32,768 time domain points, 32 scans, and a relaxation delay of 2.7 seconds. The water resonance was suppressed by a gated irradiation centered on the water frequency. The spectra were phased, manually baseline corrected, and referenced to sodium 3-trimethylsilyl-2,2,3,3-tetradeuteropropionate using the Bruker TopSpin-3.5 software package. Spectral assignments were based on literature values.[@bib34]

Statistical Methods {#appsec1.13}
-------------------

All analyses were conducted within the framework of mixed models analysis of variance. Variation between experiments conducted on separate days was modeled as a random effect. Data transformations were evaluated to meet normality assumptions. Repeated measures in sampling (eg, multiple fields analyzed within mice from the *in vivo* study) were modeled using a compound symmetry covariance structure. Goodness-of-fit was evaluated via analysis of model residuals. Comparisons between groups were performed as described earlier. Statistical analysis was conducted using GraphPad Prism version 6 for Mac OS X (Cupertino, CA) (GraphPad Software, Inc, San Diego, CA).Supplementary Figure 1**Mutant KRAS exosomes enhance cell-cycle progression and proliferation of DKs-8 cells cultured in low-glucose medium.** DKs-8 cells were incubated with DKs-8 or DKO-1 exosomes or mock-treated (*A*) for 48 hours or (*B*) for times shown. Cell-cycle state was assayed by Hoechst staining followed by flow cytometric analysis (n = 3 in triplicate). (*C*) Growth of exosome-treated DKs-8 cells after 120 hours as determined by relative fluorescence intensity (RFU) of stained nuclei. (*A* and *C*) \**P* \< .05 for comparison indicated. (*B*) \**P* \< .05 for pairwise comparisons between DKO-1 exosomes vs DKs-8 exosomes or mock treatment.Supplementary Figure 2**Characterization of exosome effects in vitro.** (*A*) Normal mouse colonoid cultures were characterized by antibody staining as indicated. Most epithelial cells express non--cell-surface E-cadherin (E-Cad; green); smooth muscle actin (SMA; red) marks pericryptal fibroblasts. T-antigen (green) indicates the presence of young adult mouse colon (YAMC) cells. Na/K adenosine triphosphatase (ATPase) (green) marks epithelial cells separate from Pan-Cadherin--expressing cells. Most epithelial cells express cytokeratin (CYT) 8/18 (green). (*B*) Representative images for panel *C*. Redox ratios for (*C*) normal mouse colonoids cultured in Matrigel, (*D*) normal mouse colonic cells cultured on plastic, and (*E*) DKs-8 cells exposed for 48 hours to the treatments indicated. Data are mean normalized redox ratio ± SEM. \**P* \< .05.Supplementary Figure 3**Metabolic imaging in vivo.** WT or *Apc*^*Min/*+^ mice were injected with DKs-8 or DKO-1 exosomes or mock-treated. (*A*) Colonic tumors were removed and the normalized redox ratio was calculated. Y-axis plots redox ratios of individual cells showing distribution of ratios for pair-wise comparisons. Mutant KRAS DKO-1 exosomes show a shift toward higher redox ratios. (*B*) ^18^F-FSPG uptake was monitored by positron emission tomography imaging; representative positron emission tomography images are shown with *brackets* highlighting colonic regions of interest with corresponding magnetic resonance image in bottom panel. (*C*) Whole-mount and colonoscopic images from mice in each treatment group. \*Distal colonic tumors.Supplementary Figure 4**Morphologic and biochemical analysis of exosomes.** (*A*) DKO-1 exosomes show characteristic appearance by transmission electron microscopy (Materials and Methods). (*B*) DKs-8 and DKO-1 exosomes have a similar mean particle diameter. Four independent preparations of DKs-8 and DKO-1 exosomes were subjected to nanoparticle tracking analysis (Materials and Methods). Data are plotted as average diameter ± SD. (*C*) Immunoblot analysis of DKO-1 cell--derived exosomes fractionated by iodixanol density gradient centrifugation. (*D*) Immunoblot analysis of DLD-1 parental and GLUT-1 KO cells and exosomes.
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